{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:49:47Z","timestamp":1775278187718,"version":"3.50.1"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7090-26","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T22:08:47Z","timestamp":1774908527000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Rapidly Progressive Interstitial Lung Disease with Coexisting Anti-MDA5 and Anti-OJ Antibodies Successfully Treated with Intensive Immunosuppression and Plasma Exchange"],"prefix":"10.2169","author":[{"given":"Daisuke","family":"Nakatani","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Saitama Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Yamakawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saitama Red Cross Hospital, Japan"},{"name":"Department of Internal Medicine, Division of Respiratory Medicine, Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Akasaka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saitama Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Machida","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saitama Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Kanai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Saitama Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Oba","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saitama Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saitama Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Matsushima","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saitama Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hozumi H, Enomoto N, Kono M, et al. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis\/dermatomyositis-associated interstitial lung disease: a retrospective case control study. PLoS One 10: e0120313, 2015.","DOI":"10.1371\/journal.pone.0120313"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Nombel A, Fabien N, Coutant F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol 12: 773352, 2021.","DOI":"10.3389\/fimmu.2021.773352"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sehgal S, Patel A, Chatterjee S, et al. Idiopathic inflammatory myopathies related lung disease in adults. Lancet Respir Med 13: 272-288, 2025.","DOI":"10.1016\/S2213-2600(24)00267-4"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Tomohiro K, Fujikawa K, Horai Y, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology 51: 1278-1284, 2012.","DOI":"10.1093\/rheumatology\/ker518"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One 8: e60442, 2013.","DOI":"10.1371\/journal.pone.0060442"},{"key":"6","unstructured":"6. Sekiya R, Nishio T, Tomioka H, et al. A case of anti-OJ antibody positive ILD presenting with acute respiratory failure. Ann Jpn Respir Soc 6: 4, 2017 (in Japanese)."},{"key":"7","unstructured":"7. Liang X, Wu J, Ren H, et al. Clinical features and prognosis of idiopathic inflammatory myopathies with coexistent multiple myositis-specific antibodies. Clin Exp Rheumatol 43: 211-220, 2025."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Li X, Liu Y, Cheng L, et al. Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease. J Clin Lab Anal 36: e24726, 2022.","DOI":"10.1002\/jcla.24726"},{"key":"9","unstructured":"9. Johnson SR, Bernstein EJ, Bolster MB, et al. 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care Res (Hoboken) 76: 1182-1200, 2024."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sasaki N, Nakagome Y, Kojima A, et al. Early Initiation of Plasma Exchange Therapy for Anti-MDA5+Dermatomyositis with Refractory Rapidly Progressive Interstitial Lung Disease. Intern Med 63: 213-219, 2024.","DOI":"10.2169\/internalmedicine.1410-22"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Eggleston RH, Baqir M, Varghese C, et al. Clinical Outcomes With and Without Plasma Exchange in the Treatment of Rapidly Progressive Interstitial Lung Disease Associated With Idiopathic Inflammatory Myopathy. J Clin Rheumatol 29: 151-158, 2023.","DOI":"10.1097\/RHU.0000000000001923"},{"key":"12","unstructured":"12. Japanese Respiratory Society, Japanese College of Rheumatology. Joint Committee for the Guidelines for the Diagnosis and Treatment of Interstitial Lung Disease Associated with Connective Tissue Diseases (CTD-ILD) 2025. Medical Review Co., Ltd., Tokyo, Japan, 2025: 86-116 (in Japanese)."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yanagihara T, Suzuki K, Egashira A, et al. Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies. Respir Med Case Rep 31: 101272, 2020.","DOI":"10.1016\/j.rmcr.2020.101272"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Chen X, Jiang W, Jin Q, et al. Nintedanib could potentially lead to improvements in anti-melanoma differentiation-associated 5 dermatomyositis-associated interstitial lung disease. Clin Exp Rheumatol 42: 386-393, 2024.","DOI":"10.55563\/clinexprheumatol\/c0i032"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 13: 367-371, 2014.","DOI":"10.1016\/j.autrev.2014.01.022"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Chen X, Zhang L, Jin Q, et al. The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients. Front Immunol 13: 987841, 2022.","DOI":"10.3389\/fimmu.2022.987841"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Naniwa T, Tamechika S, Okazaki Y, Maeda S, Kuwana M. Coexistence of anti-melanoma differentiation-associated gene 5 and anti-aminoacyl-transfer RNA synthetase antibodies in a patient with dermatomyositis and rapidly progressive and relapsing interstitial lung disease. Mod Rheumatol Case Rep 1: 3-8, 2017.","DOI":"10.1080\/24725625.2016.1253650"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Takeuchi Y, Hashimoto M, Nakashima R, et al. Anti-EJ, anti-MDA5 double-positive chronic clinically amyopathic dermatomyositis: a case report. Rheumatol Adv Pract 2: rky022, 2018.","DOI":"10.1093\/rap\/rky022"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Li ZY, Gill E, Mo F, Reyes C. Double anti-PL-7 and anti-MDA-5 positive Amyopathic Dermatomyositis with rapidly progressive interstitial lung disease in a Hispanic patient. BMC Pulmonary Med 20: 220, 2020.","DOI":"10.1186\/s12890-020-01256-x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hama S, Higashida-Konishi M, Akiyama M, et al. Dermatomyositis which was double positive for anti-MDA5 and anti-ARS antibodies that was successfully treated by intensive immunosuppressive therapy. Intern Med 61: 1085-1091, 2022.","DOI":"10.2169\/internalmedicine.8579-21"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hiramatsu T, Murano M, Nakai S, et al. Clinically amyopathic dermatomyositis with interstitial lung disease double-positive for anti-MDA5 and anti-PL12 antibodies. Respir Med Case Rep 36: 101606, 2022.","DOI":"10.1016\/j.rmcr.2022.101606"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Fu H, Sun S, Zhang H, et al. Coexistence of anti-MDA5 and anti-PL-7 in a patient with dermatomyositis: a case report. Clin Case Rep 11: e6840, 2023.","DOI":"10.1002\/ccr3.6840"},{"key":"23","unstructured":"23. Fujiwara M, Watanabe H, Goda M, et al. A case of dermatomyositis double positive for anti-melanoma differentiation-associated gene 5 and anti-aminoacyl-tRNA synthetase antibodies with treatment-resistant myositis. Ann Jpn Respir Soc 13: 4, 2024."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Egashira R. High-resolution CT findings of myositis-related interstitial lung disease. Medicina (Kaunas) 57: 692, 2021.","DOI":"10.3390\/medicina57070692"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Hozumi H, Fujisawa T, Nakashima R, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease. Respir Med 121: 91-99, 2016.","DOI":"10.1016\/j.rmed.2016.10.019"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Chino H, Sekine A, Baba T, et al. Interstitial lung disease with anti-melanoma differentiation-associated protein 5 antibody: rapidly progressive perilobular opacity. Intern Med 58: 2605-2613, 2019.","DOI":"10.2169\/internalmedicine.2328-18"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Ghirardello A, Rampudda M, Ekholm L, et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) 49: 2370-2374, 2010.","DOI":"10.1093\/rheumatology\/keq281"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Espinosa-Ortega F, Holmqvist M, Alexanderson H, et al. Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies. Ann Rheum Dis 78: 858-860, 2019.","DOI":"10.1136\/annrheumdis-2018-214690"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7090-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T03:55:46Z","timestamp":1775274946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7090-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7090-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7090-26"}}